PEN-866 is under clinical development by Tarveda Therapeutics and currently in Phase II for Small-Cell Lung Cancer. According to GlobalData, Phase II drugs for Small-Cell Lung Cancer have a 26% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how PEN-866’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
PEN-866 overview
PEN-866 is under development for the treatment of small cell lung cancer, colorectal cancer, gastric adenocarcinoma, ovarian cancer and pancreatic adenocarcinoma. The drug candidate is a Hsp90 inhibitor linked to SN-38 via a cleavable chemical linker. SN-38 acts by targeting topoisomerase I. The drug candidate is developed based on Hsp90-inhibitor drug conjugates (HDCs) platform technology. It is administered through intravenous route. It was also under development for the treatment of non-small cell lung cancer,triple negative breast cancer, bladder cancer and melanoma, liposarcoma, Ewing sarcoma, rhabdomyosarcoma.
Tarveda Therapeutics overview
Tarveda Therapeutics (Tarveda) formerly Blend Therapeutics is a clinical stage bio pharmaceutical company that discovers and develops miniaturized novel biologic drug conjugates. The company develops targeted anti-cancer medicines for advancing the treatment for solid tumors. Its pipeline products include PEN-221, a miniature drug conjugate used for the treatment of neuroendocrine small cell lung and other cancers and PEN-866 is used for the treatment of small cell lung and pancreatic cancers. The company operates through other pharmaceutical companies to develop its proprietary Pentarins and new miniaturized biologic drug conjugates. Tarveda is headquartered in Watertown, Massachusetts, the US.
For a complete picture of PEN-866’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
